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Abstract
Background—In order to ensure accurate survival estimates, population-based cancer registries 
must ascertain all, or nearly all, patients diagnosed with cancer in their catchment area, and obtain 
complete follow-up information on all deaths that occurred among registered cancer patients. In 
the US, linkage with state death records may not be sufficient to ascertain all deaths. Since 1979, 
all state vital statistics offices have reported their death certificate information to the National 
Death Index (NDI).
Objective—This study was designed to measure the impact of linkage with the NDI on 
population-based relative and cancer cause-specific survival rates in the US.
Methods—Central cancer registry records for patients diagnosed 1993–1995 from California, 
Colorado, and Idaho were linked with death certificate information (deaths 1993–2004) from their 
individual state vital statistics offices and with the NDI. Two databases were created: one 
contained incident records with deceased patients linked only to state death records and the second 
database contained incident records with deceased patients linked to both state death records and 
the NDI. Survival estimates and 95% confidence intervals from each database were compared by 
state and primary site category.
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Results—At 60 months follow-up, 42.1–48.1% of incident records linked with state death 
records and an additional 0.7–3.4% of records linked with the NDI. Survival point estimates from 
the analysis without NDI were not contained within the corresponding 95% CIs from the NDI 
augmented analysis for all sites combined and colorectal, pancreas, lung and bronchus, breast, 
prostate, non-Hodgkin lymphoma, and Kaposi sarcoma cases in all 3 states using relative survival 
methods. Additional combinations of state and primary site had significant survival estimate 
differences, which differed by method (relative versus cause-specific survival).
Conclusion—To ensure accurate population-based cancer survival rates, linkage with the 
National Death Index to ascertain out of state and late registered deaths is a necessary process for 
US central cancer registries.
Keywords
Death certificate accuracy; National Death Index; Cancer survival
1. Introduction
Cancer registries play a critical role in monitoring effective cancer control activities by 
providing population-based incidence and survival data. In addition, information on cancer 
survival can be used to evaluate the overall effectiveness of healthcare delivery to cancer 
patients [1,2].
Net survival estimates the probability of surviving cancer in the absence of other causes of 
death and provides a means for tracking survival over time and across populations with 
different life expectancies. The two methods for estimating net survival are relative survival 
(i.e., the ratio of the observed survival in the cancer patient cohort to the expected survival 
from a comparable group in the general population) and cause-specific survival (i.e., 
probability of death from a specific cause where deaths from all others causes are treated as 
censored observations).
In order to ensure valid relative and cause-specific survival estimates, population-based 
cancer registries must first ascertain all, or nearly all, patients diagnosed with cancer in their 
catchment area [3], and second, obtain complete follow-up information on all deaths that 
occurred among registered cancer patients [4,5].
Ascertaining deaths can be particularly challenging to cancer registry staff as the resources 
required to conduct follow-up increases as the number of registered patients increases. Over 
time, these numbers will continue to increase due to the maturity of the cancer registry, a 
growing and aging population, and improved survival [6].
To assist in the ascertainment of cancer patients who may have been missed at the time of 
their diagnosis, or who may have been diagnosed with cancer only at the time of their death, 
cancer registries routinely link their incidence data with death certificate data from their 
jurisdictional vital records offices [7]. During this linkage process, known as death 
clearance, the cancer registry database can be updated with cause and date of death 
information among deceased incident cases.
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Over the past several decades, advances in early detection and treatment have resulted in 
increased survival time for cancer patients [8]. Patients may move from one jurisdiction to 
another within the same country between the time of their diagnosis and their death and, 
depending on practices regarding the recording of deaths in the country, the cancer registry 
reporting the incident case may not learn of the patient’s death. In the United States (US), 
deaths are recorded in the state where the decedent expired and shared, if different, with the 
state of residence at the time of death. This may or may not be the state in which a person 
resided when they were diagnosed with cancer. Another limitation may result from the 
exchange of information between state vital statistics offices (VSO). For example, a cancer 
patient may seek treatment out of state and subsequently die. The VSO where the death 
occurred may be slow to report the death to the VSO in the state where the patient resided, 
or the VSO may place restrictions on the use of death certificate data in a way that precludes 
or impedes the use of the death records in linkages with cancer registry records [9]. 
Therefore, linkage with state death records may not be sufficient to ascertain all deaths that 
occurred among cancer patients registered in statewide or metropolitan-area based cancer 
registries.
The US Centers for Disease Control and Prevention (CDC)’s National Center for Health 
Statistics (NCHS) maintains the National Death Index (NDI). Since 1979, VSOs in all 50 
states, Puerto Rico, and the Virgin Islands have reported their death certificate information 
to the NDI [10,11]. Cancer registries are encouraged to link their incidence records with 
both state death records and the NDI for the purpose of ascertaining deaths and updating 
date and cause of death information [9]. Record linkage with the NDI has been used with 
both adult and pediatric cohort studies [12–17].
The present study uses secondary data from the Accuracy of Cancer Mortality Statistics 
Based on Death Certificates (ACM) study [18]. The main objective of the ACM study was 
to characterize the concordance between cancer cause of death information from death 
certificates and primary cancer site at diagnosis recorded in US cancer registries [19]. Cases 
included in the ACM study had follow-up for at least 9 years, and data collected for the 
ACM study provided a unique opportunity to investigate the impact of NDI linkages on 
survival estimates by comparing survival rates based on deaths ascertained solely by state 
death record linkages with rates based on linkage to state death records and the NDI.
2. Materials and methods
The ACM study has been described in detail elsewhere [18]. Briefly, population-based 
central cancer registries in California, Colorado, and Idaho were selected because they met 
study eligibility criteria including but not limited to the following: the registry was statewide 
and population-based; cancer incidence data were complete and high quality (e.g., met 
publication criteria [20]); and the registry performed routine death clearance with state death 
records. In addition, these registries agreed to send their incidence data to the NDI to 
ascertain deaths that were not recorded in their state vital records offices. If a death was 
ascertained via the state process, the record was not sent for NDI linkage.
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In the current study, we investigated the impact of NDI linkage on 5-year cancer survival 
rates based on incident cases diagnosed between January 1, 1993 through December 31, 
1995 and deaths that occurred up to 5 years after diagnosis.
2.1. Analysis
Data from the three statewide cancer registries were combined into one dataset using SAS 
(Version 9.2, Cary, NC), and two datasets were subsequently created and processed using 
SEER*Prep (Version 2.4.5, Information Management Services, Inc., Silver Spring, MD). A 
field demarcating the source of follow-up information at the state cancer registry was used 
to identify deaths ascertained through NDI linkages. To maintain consistency between the 
datasets, all patients with vital status alive were censored at the end of the study period, 
December 31, 2004. The first dataset included deaths ascertained through state processes 
and NDI linkages (NDI augmented file). In order to keep sample sizes consistent in both 
datasets, the second dataset (NDI censored file) was created with all NDI deaths censored at 
the end of the study period (vital status alive as of December 31, 2004) as if the NDI linkage 
had not been performed. A small proportion of deaths was ascertained via follow-up by 
hospitals and other sources and lacked cause of death information (1.6% in California, 1.0% 
in Colorado, and 0.7% in Idaho). These are included in the totals for state source of death 
ascertainment in Table 1 and included in the survival analyses as is the general practice in 
the states.
Analysis was performed using the survival functions in SEER*Stat (Version 7.0.5, 
Information Management Services, Inc., Silver Spring, MD). Cancer site-specific 5-year 
survival rates were generated according to SEER primary site recodes that group cases by 
major site/histology categories and are commonly used in the reporting of cancer statistics 
[21]. Ninety-five percent confidence intervals (CIs) for the survival functions were based on 
the log–log transformation. Parallel survival analyses were conducted on the two datasets in 
order to compare site-specific survival rates with NDI (augmented) and without NDI 
(censored) linkage results. Thus, the comparison is between death ascertainment solely by 
state processes versus state processes supplemented by the NDI. Differences between 
survival rates were calculated by subtracting the value from the NDI augmented analysis 
from the NDI censored analysis, such that the differences were all in the positive direction. 
As there is no formal statistical test to compare survival estimates on (nearly) the same 
population using different analysis methods with grouped data, we considered as significant 
those rate differences where point estimates from the NDI censored analysis were not 
contained within the corresponding 95% CIs from the NDI augmented analysis, which we 
considered to be the gold standard.
Calculations were performed using the actuarial method on monthly follow-up intervals, and 
the cumulative summary survival rate at 60 months (5 years) is shown. For the relative 
survival analysis, the expected survival table available in SEER*Stat titled “U.S. 1970–2006 
by individual year (White, Black, Other (AI/API) All races for Other Unspec 1991+ and 
Unknown)” was used (AI/API refers to American Indian or Alaskan Native/Asian or Pacific 
Islander) [22]. Ederer II was selected as the cumulative expected method for relative 
survival; for expected survival, values from the expected survival table were matched to 
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each patient by age, sex, race, and year and considered to be at risk until the corresponding 
cancer patient died or was censored [23]. For the cause-specific survival analyses, two 
definitions were used: the first (narrow) definition required a match between the primary site 
at diagnosis and the cancer-specific death whereas the second (broad) definition required a 
match with any cancer cause of death [18].
The analyses were limited to data on first (or only) primary invasive cases among persons 
diagnosed with cancer. Cases reported solely by death certificate or autopsy were excluded 
from all analyses, as were cases missing age, sex, or with an invalid race code. In order to 
maintain consistency of sample sizes across analyses (relative versus cause-specific), 
deceased cases with missing or unknown cause of death were censored at the date of death 
in the cause-specific analyses. Such deaths would be considered events in relative survival 
where fact but not cause of death is necessary for the analysis.
2.1.1. Human subjects protections—The study protocol was formally reviewed for 
protection of human subjects in research, and was exempted by CDC and ICF Macro 
(Bethesda, MD), yet approved by the institutional review boards governing the individual 
state cancer registries. To ensure the protection of patient confidentiality and the stability of 
the survival estimates, analysis cells with a frequency of five or fewer cases were suppressed 
in tables.
3. Results
Table 1 shows the numbers of eligible cases diagnosed between 1993 and 1995 and the 
numbers of deaths that were ascertained via state processes and via NDI linkages at 60 
months of follow-up, by state of residence at diagnosis and primary site category. Among 
306,422 incident cases in California, 147,278 (48.1%) deaths were ascertained via state 
processes and 2224 (0.7%) cases linked with the NDI. Among 35,261 incident cases in 
Colorado, 14,845 (42.1%) deaths were ascertained via state processes and 768 (2.2%) linked 
with the NDI. Among 11,282 incident cases in Idaho, 4869 (43.2%) deaths were ascertained 
via state processes and 387 (3.4%) linked with the NDI. Linkage with the NDI identified 
additional deaths among cancer patients in all 3 states and in all primary site categories 
examined. The proportion of deaths identified through NDI linkages at 60 months of follow-
up varied by state (1.5% in California, 4.9% in Colorado, and 7.4% in Idaho). Extending the 
follow-up period to the end of the study (December 31, 2004) resulted in a higher proportion 
of deaths identified through NDI linkages (2.2% in California, 6.4% in Colorado, and 9.0% 
in Idaho).
The impact of NDI linkage on survival rates was evaluated by examining the differences 
between rates based on state processes and linkages with the NDI (NDI augmented) and 
rates based solely on state death ascertainment (NDI censored).
Table 2 shows 5-year relative survival rates, 95% CIs and rate differences comparing NDI 
censored with NDI augmented rates. For California, Colorado and Idaho, significant rate 
increases were seen for all sites combined (0.9%, 2.6%, and 4.2% respectively), colorectal 
cases (1.0%, 3.1%, and 5.1% respectively), pancreas cases (1.0%, 3.8%, and 4.2% 
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respectively), lung and bronchus cases (1.4%, 4.3%, and 7.5% respectively), breast cases 
(0.5%, 1.2%, and 2.2% respectively), prostate cases (0.6%, 1.6%, and 3.5% respectively), 
non-Hodgkin lymphoma cases (1.0%, 3.5%, and 6.9% respectively), and Kaposi sarcoma 
cases (2.7%, 10.1%, and 36.7% respectively). For both Colorado and Idaho, rates differed 
significantly for leukemia cases (3.9% and 5.9% respectively). For Colorado, rates differed 
significantly for stomach, liver and bile duct, and brain cases (4.0%, 5.4%, and 4.8% 
respectively). Within each state, the largest rate difference occurred for Kaposi sarcoma.
Table 3 shows 5-year cause-specific (narrow definition) survival rates, 95% CIs and rate 
differences comparing NDI censored with NDI augmented rates. Fewer differences were 
noted and they were smaller. For California, Colorado and Idaho, significant rate differences 
were seen for all sites combined (0.5%, 1.5%, and 2.2% respectively) and for cancers of the 
lung and bronchus (1.3%, 3.9%, and 6.7% respectively). For California and Colorado, rates 
also differed significantly for colon and rectum cases (0.6% and 1.9% respectively) and 
pancreas cases (1.0% and 4.0% respectively). Rates differed significantly for breast cases 
(0.8%) and brain cases (4.4%) in Colorado and non-Hodgkin lymphoma cases in Idaho 
(5.2%). Kaposi sarcoma cases are not included in Tables 3 and 4 because for these cases the 
underlying cause of death is coded to HIV/AIDS.
Table 4 shows 5-year cancer cause (broad definition) survival rates, 95% CIs and rate 
differences comparing NDI augmented with NDI censored rates. For California, Colorado 
and Idaho, significant rate differences were seen for all sites combined (0.6%, 1.7%, and 
2.6% respectively), pancreas cases (1.0%, 3.5%, and 3.7% respectively), and lung and 
bronchus cases (1.3%, 3.9%, and 6.4% respectively). For California and Colorado, rates also 
differed significantly for colon and rectum cases (0.7% and 2.0% respectively). Rates 
differed significantly for breast cases in California (0.4%), brain cases in Colorado (4.8%) 
and non-Hodgkin lymphoma cases in Idaho (5.4%).
4. Discussion
Population-based survival is an important measure of the cancer burden because it measures 
the actually achieved survival for all patients in the general population regardless of age, 
health status, stage of disease and access to care [24]. This information can be used by 
cancer control planners to identify groups who may not experience optimal outcomes 
following a diagnosis of cancer, and can help target early diagnosis and treatment activities 
in areas most in need.
Identifying all, or nearly all, deaths is critical to obtaining valid survival estimates. Missing 
only a small proportion of deaths can result in spuriously high survival proportions 
particularly among highly lethal cancers [3–5] and as length of follow-up increases [4].
During routine death clearance, central cancer registries can update vital status and date and 
cause of death information from intra-jurisdictional death records. In this study of three US 
states, routine death clearance identified the vast majority of deaths. However, the NDI 
linkage did ascertain additional deaths in all primary site categories investigated and in all 
three states, and was critical for obtaining valid survival estimates, particularly for cancer 
sites with large numbers of deaths (all sites combined, colorectal, lung and bronchus, breast, 
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and prostate) and the more lethal cancers (lung and bronchus, liver and bile duct, and 
pancreas).
Variation in percentages of out-of-state deaths in this study may be partly explained by 
interstate migration patterns and the location of population centers near adjacent states. In 
California, large cities are mostly coastal, and neighboring states generally do not have large 
population centers near the population centers in California. There is extensive interstate 
migration in the US. In 2010, 2.2% of the US populations resided in a different state 1 year 
earlier [25]. In 20 of 51 jurisdictions (states/District of Columbia), including Colorado and 
Idaho, annual interstate migration was 3.0% or greater. In California, annual interstate 
migration was tied for lowest in the US at 1.2%. This partly explains the differences among 
states in this study in the impact of NDI linkages on cancer survival rates. The results from 
Colorado and Idaho are likely more representative of many other US states than are the 
California results.
This study did not investigate the impact of NDI linkage on survival estimates with longer 
than 5 years of follow up. However, a study using data from the Finland Cancer Registry 
demonstrated that completeness of death ascertainment was increasingly important with 
longer length of follow up [4]. For this reason, linkage with NDI is also likely to be 
important with the reporting of longer term survival estimates.
In order to report valid survival estimates at the regional and national level, it will be 
important for all US registries to conduct NDI linkages and report their results to their 
respective federal cancer surveillance programs: the CDC’s National Program of Cancer 
Registries and the NCI’s Surveillance, Epidemiology and End Results (SEER) Program. The 
precision or statistical power of survival estimates for any and all sites will be improved as 
data are pooled from multiple cancer registries.
Theoretically, the NDI should identify all deaths among US residents and in combination 
with state death records appears adequate to identify greater than 99% of all deaths (personal 
communications with C McLaughlin, New York State Department of Health and ML 
Almon, Georgia Comprehensive Cancer Registry). The development of matching algorithms 
has helped facilitate the processing of results from the NDI with its large volume of output, 
potential for multiple NDI matches per registry record submitted, and cryptic output [11]. 
However, in practice, NDI misses some deaths as evidenced through sensitivity analyses 
when information on known decedents failed to successfully link with the NDI [26]. Other 
sources of death information include hospital-based cancer registries and the Social Security 
Death Index (SSDI); however, while these two sources are adequate for updating vital status 
and date of death, SSDI does not have, and hospital-based cancer registries in the US often 
do not have, coded cause of death information which is necessary for cause-specific cancer 
survival analysis.
Passive follow-up methods, such as state death certificate and NDI linkages in the US, may 
fail to ensure complete follow-up of cancer cases due to international migration or poor data 
quality that prevents linkage. Using passive follow-up methods alone, these cases are 
censored alive at the study cutoff, and such missed deaths may bias survival statistics [4,5]. 
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However, conducting (active) follow-up on alive patients in the presence of near complete 
death ascertainment has been shown to be of lesser importance [5]. For these reasons, 
registry staff should pay particular attention to identifying and following “immortal patients” 
– patients reported as alive despite being diagnosed with a lethal cancer or with advanced 
disease, or patients who are reported as alive well past their normal life expectancy.
While not a main objective of this study, it is worth noting the influence of cause and source 
of death data on survival estimates depending on the analytic method. Relative survival 
requires fact but not cause of death information. Hence, it is the preferred method of 
estimating population-based survival where information on cause of death – routinely 
reported by death certificates – may not be available or may not accurately reflect the 
mortality experience of the cancer patient [22]. Cause of death information comes from 
death certificates, and the accuracy of the information may depend on the certifier [27]. For 
example, the site of cancer recurrence or metastasis may be listed as the cause of death 
instead of the primary site of the cancer.
Relative survival requires life tables that are matched to the cancer population by age, sex, 
race and/or ethnicity, geographic area and, ideally, other risk factors for the cancer under 
study (e.g., socio-economic status, smoking status). However, relative survival can be biased 
and under- or over-estimate survival if there is a mismatch between the life table and the 
cancer patient cohort under study [28]. Because life tables appropriate for the purpose of the 
study (e.g., by state or socio-economic status) may be unavailable, cause-specific survival is 
sometimes used as an alternative to relative survival. The US National Cancer Institute has 
developed and published a classification variable for cause of death associated with site-
specific cancer diagnoses that takes into account likely misclassification of cause of death 
while not overly expanding the causes of death that are associated with each cancer 
diagnosis [29]. This broader definition of cause-specific survival gave estimates that more 
closely approximate those of relative survival.
5. Limitations
Survival estimates from this study were calculated for the purpose of comparing 
jurisdictional death clearance with national death linkages, and were not intended to 
represent the survival experience of cancer patients in the three states. The field demarcating 
the source of follow-up information used to identify NDI linkages may have been 
incomplete in earlier years of death in some states (personal communications with R 
Rycroft, Colorado Central Cancer Registry), meaning the differences in survival rates 
between NDI censored and NDI augmented datasets may be understated. Furthermore, as 
life expectancy varied between states in the US [28], comparisons among the three registries 
are not valid because relative survival estimates were not age-standardized nor were state 
specific life tables used to adjust for background mortality.
6. Conclusion
In the US, linkage with the NDI to ascertain out of state and late registered deaths is a 
necessary process for central cancer registries to calculate accurate population-based cancer 
survival rates. Linkage with state death records alone appears inadequate for reporting valid 
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population-based cancer survival rates using either relative or cause-specific analytic 
methods. These results may be germane to other disease registries in jurisdictions that rely 
on record linkage with death notifications in the registration area for mortality follow-up.
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ACM Accuracy of Cancer Mortality Statistics Based on Death Certificates
CDC Centers for Disease Control and Prevention
ICD International Classification of Diseases
KS Kaposi sarcoma
NAACCR North American Association of Central Cancer Registries
NCHS National Center for Health Statistics
NDI National Death Index
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NPCR National Program of Cancer Registries
SEER Surveillance, Epidemiology and End Results
UCD underlying cause of death
US United States of America
USCS United States Cancer Statistics
VSO vital statistics office (state)
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